公司资料
MDxHealth 股价、新闻与催化剂
- 股票代码:
- MDXH
- 交易所:
- NASDAQ
- 行业:
- MedTech
- 所在地:
- Belgium and listed in the U
股票表现
0.86 USD (+5.89%)
收盘价
最后更新: 2026年8月17日
32.9M USD
市值
股价为何变动
As of Aug 17, 2026, MDXH closed up 5.89% at $0.8556. No new same-company headline was identified in the current news window.
公司概览
Precision Urologic Diagnostics
MDxHealth provides molecular tests that support diagnosis, risk assessment, and treatment decisions in prostate cancer and other urologic diseases.
Prostate Cancer Menu
The company’s portfolio spans pre-biopsy risk assessment, tissue-based prognostic testing, and post-treatment monitoring, using genomic, epigenomic, and exosomal technologies.
ExoDx Integration
The acquired ExoDx urine-based prostate test broadens the diagnostic menu and is being integrated into MDxHealth’s laboratory, sales, and reimbursement infrastructure.
Portfolio Refocus
MDxHealth is exiting the Resolve UTI business to concentrate investment on prostate cancer and related urologic oncology opportunities.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。